Aclaris Therapeutics Inc. (NASDAQ:ACRS) had its price objective upped by equities research analysts at Jefferies Group from $23.00 to $31.00 in a report issued on Monday. The brokerage currently has a “buy” rating on the stock. Jefferies Group’s target price would indicate a potential upside of 27.15% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. Guggenheim started coverage on shares of Aclaris Therapeutics in a research note on Friday, June 10th. They issued a “buy” rating and a $35.00 target price for the company. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $31.25.

Aclaris Therapeutics (NASDAQ:ACRS) opened at 24.38 on Monday. The firm has a 50-day moving average of $21.05 and a 200 day moving average of $19.69. The firm’s market capitalization is $522.10 million. Aclaris Therapeutics has a 12 month low of $10.99 and a 12 month high of $33.88.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.01. Equities research analysts forecast that Aclaris Therapeutics will post ($2.61) earnings per share for the current year.

In other news, insider Kamil Ali-Jackson sold 3,738 shares of the firm’s stock in a transaction that occurred on Friday, August 26th. The shares were sold at an average price of $20.35, for a total value of $76,068.30. Following the completion of the transaction, the insider now directly owns 20,289 shares in the company, valued at $412,881.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ra Capital Management, Llc sold 525,550 shares of Aclaris Therapeutics stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $24.19, for a total transaction of $12,713,054.50. The disclosure for this sale can be found here. 46.40% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the stock. Nationwide Fund Advisors raised its stake in shares of Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock valued at $106,000 after buying an additional 1,838 shares during the last quarter. Tocqueville Asset Management L.P. bought a new stake in shares of Aclaris Therapeutics during the second quarter valued at about $185,000. Teachers Advisors Inc. raised its stake in shares of Aclaris Therapeutics by 91.0% in the second quarter. Teachers Advisors Inc. now owns 14,212 shares of the company’s stock valued at $262,000 after buying an additional 6,772 shares during the last quarter. Swiss National Bank bought a new stake in shares of Aclaris Therapeutics during the second quarter valued at about $283,000. Finally, Sabby Management LLC bought a new stake in shares of Aclaris Therapeutics during the second quarter valued at about $292,000. Institutional investors and hedge funds own 71.39% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

5 Day Chart for NASDAQ:ACRS

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.